# A Study on Peginterferon Alfa-2b Combined With NAs in Compensated HBV Cirrhosis

> **NCT07183293** · NA · NOT_YET_RECRUITING · sponsor: **Xiamen Humanity Hospital** · enrollment: 30 (estimated)

## Conditions studied

- HBV-related Liver Cirrhosis

## Interventions

- **DRUG:** Peginterferon alfa-2b combined with NAs
- **DRUG:** NAs

## Key facts

- **NCT ID:** NCT07183293
- **Lead sponsor:** Xiamen Humanity Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10
- **Primary completion:** 2027-03
- **Final completion:** 2031-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07183293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07183293, "A Study on Peginterferon Alfa-2b Combined With NAs in Compensated HBV Cirrhosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07183293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*